UroGen Pharma Ltd. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
UroGen reported Q2 2026 ZUSDURI revenue of $50.4M (up 73% QoQ), with 1,444 activated care sites and 452 prescribers (45% repeat rate). The FDA issued a Notice of Allowance for a new patent extending ZUSDURI/UGN-103 protection to July 2044. Pipeline advances: UGN-103 NDA submission on track for Q3 2026; UGN-501 Phase 1 trial planned Q4 2026. Operating expenses raised to $260–270M for 2026. JELMYTO revenue guidance remains $97–101M; Teva settlement allows generic launch September 15, 2030.
Why this rating
Strong ZUSDURI commercial traction (8.1% of market cap annualized) and extended IP protection materially strengthen franchise. However, modest cash position ($108M = 17% of market cap) and mounting operating costs ($260–270M guidance) offset gains. Pipeline expansion is encouraging but early-stage.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.